Orange Biomed to Present New A1C Research at DTM 2026

Orange Biomed will present a scientific poster and join the Startup Showcase at the 26th Annual Diabetes Technology Meeting in Washington, D.C., on Oct. 27-29. The company is using the event to highlight new A1C repeatability research as it advances toward FDA submission and potential over-the-counter clearance for its handheld meter.

Why it matters: - Orange Biomed is using DTM 2026 to showcase progress on a pocket-sized A1C meter designed for home use. - The company is advancing toward a U.S. medical device launch, with ISO 13485 certification already in hand and a planned FDA 510(k) submission ahead. - The meeting gives Orange Biomed direct access to clinicians, researchers and industry partners focused on diabetes care.

What happened: - Orange Biomed said it will participate in the 26th Annual Diabetes Technology Meeting from Oct. 27-29 at the Hyatt Regency Crystal City in Washington, D.C. - The company will present a scientific poster and take part in the Startup Showcase. - Orange Biomed is attending DTM for the fourth consecutive year. - The event is co-hosted by the American Diabetes Association and the Diabetes Technology Society.

The details: - Orange Biomed will present an abstract titled "A Pump-Free Microfluidic Sensor for Highly Repeatable HbA1c Monitoring via Flow-Normalized RBC Velocity Variability." - The poster session is scheduled for Tuesday, Oct. 27, 2026, at 6:35 p.m. EDT in Slot #26. - The Startup Showcase is set for Wednesday, Oct. 28, 2026, from 4:35-6:35 p.m. EDT. - The study builds on repeatability research the company presented as a Late-Breaking Poster at the ADA's 86th Scientific Sessions in June 2026. - Orange Biomed's OBM rapid A1c is a reusable meter that measures A1C from a single 5 µL fingerstick blood sample and is designed to deliver results in five minutes. - The device uses a proprietary microfluidic single-cell analysis platform that measures the characteristics of individual red blood cells. - The approach does not rely on biochemical protein measurement and is less affected by interference from hemoglobin variants. - The reagent-free cartridges can be stored and shipped at room temperature. - The meter requires no recalibration. - Orange Biomed earned ISO 13485 certification for its quality management system in September. - Orange Biomed is preparing a 510(k) submission to the U.S. FDA for potential over-the-counter clearance of the OBM rapid A1c.

Between the lines: - The company is positioning its technology as a simpler alternative to conventional A1C testing, which is usually done in laboratories or clinics. - Repeated appearances at DTM suggest Orange Biomed is using the conference as a key venue for technical validation and business development. - CEO Yeaseul Park said the company wants to make A1C testing more accessible at home and help people manage diabetes more conveniently.

What's next: - Orange Biomed will present its research and meet with potential collaborators during DTM 2026. - The company will continue work toward FDA submission and possible over-the-counter clearance in the U.S. - Further progress on the OBM rapid A1c will likely center on regulatory review and broader market entry.

The bottom line: - Orange Biomed is pairing new A1C data with a clear commercialization push as it looks to turn its microfluidic meter into a home-testing product.